DK1641787T3 - Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister - Google Patents
Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonisterInfo
- Publication number
- DK1641787T3 DK1641787T3 DK04740230T DK04740230T DK1641787T3 DK 1641787 T3 DK1641787 T3 DK 1641787T3 DK 04740230 T DK04740230 T DK 04740230T DK 04740230 T DK04740230 T DK 04740230T DK 1641787 T3 DK1641787 T3 DK 1641787T3
- Authority
- DK
- Denmark
- Prior art keywords
- oxytocin antagonists
- substituted diketopiperazines
- diketopiperazines
- substituted
- oxytocin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314738A GB0314738D0 (en) | 2003-06-24 | 2003-06-24 | Novel compounds |
| PCT/EP2004/006814 WO2005000840A1 (en) | 2003-06-24 | 2004-06-22 | Substituted diketopiperazines and their use as oxytocin antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1641787T3 true DK1641787T3 (da) | 2007-09-17 |
Family
ID=27637257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04740230T DK1641787T3 (da) | 2003-06-24 | 2004-06-22 | Substituerede diketopiperaziner og deres anvendelse som oxytocinantagonister |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8071594B2 (hr) |
| EP (1) | EP1641787B1 (hr) |
| JP (1) | JP5128126B2 (hr) |
| KR (1) | KR101131378B1 (hr) |
| CN (2) | CN100404532C (hr) |
| AR (1) | AR044869A1 (hr) |
| AT (1) | ATE361295T1 (hr) |
| AU (1) | AU2004251868B2 (hr) |
| BR (1) | BRPI0411729A (hr) |
| CA (1) | CA2530310C (hr) |
| CY (1) | CY1107703T1 (hr) |
| DE (1) | DE602004006268T2 (hr) |
| DK (1) | DK1641787T3 (hr) |
| EG (1) | EG24929A (hr) |
| ES (1) | ES2285474T3 (hr) |
| GB (1) | GB0314738D0 (hr) |
| HK (1) | HK1088910A1 (hr) |
| HR (1) | HRP20070286T3 (hr) |
| IL (1) | IL172529A (hr) |
| IS (1) | IS2463B (hr) |
| MA (1) | MA27887A1 (hr) |
| MX (1) | MXPA05014068A (hr) |
| MY (1) | MY140653A (hr) |
| NO (1) | NO332677B1 (hr) |
| NZ (1) | NZ544006A (hr) |
| PL (1) | PL1641787T3 (hr) |
| PT (1) | PT1641787E (hr) |
| RU (1) | RU2343152C2 (hr) |
| TW (1) | TWI340745B (hr) |
| WO (1) | WO2005000840A1 (hr) |
| ZA (1) | ZA200509890B (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| GB0314738D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| US8716286B2 (en) | 2009-10-30 | 2014-05-06 | Glaxo Group Limited | Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione |
| BR112016029661A2 (pt) | 2014-06-16 | 2017-08-22 | Glaxosmithkline Ip Dev Ltd | retosiban para tratamento de parto prematuro |
| JP6933322B2 (ja) | 2016-01-04 | 2021-09-08 | メルク セローノ エス．エー． | ヒドロキシプロピルチアゾリジンカルボキサミド誘導体のｌ−バリネート及びその塩形態、結晶多形 |
| UA127283C2 (uk) | 2016-07-21 | 2023-07-12 | Обсева С.А. | Спосіб застосування антагоніста окситоцину для сприяння імплантації ембріона і запобігання викидню |
| CN106674031A (zh) * | 2016-11-18 | 2017-05-17 | 浙江工业大学 | R‑2‑二氢茚氨酸的制备方法 |
| CN114667141A (zh) | 2019-09-03 | 2022-06-24 | 奥布赛瓦股份公司 | 用于促进胚胎移植和预防流产的催产素拮抗剂给药方案 |
| AU2021218895A1 (en) | 2020-02-10 | 2022-09-15 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596819A (en) * | 1984-01-23 | 1986-06-24 | Warner-Lambert Company | Modified tripeptides |
| US5091387A (en) * | 1990-03-02 | 1992-02-25 | Merck & Co., Inc. | Spirocyclic oxytocin antagonists |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| US5464788A (en) * | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US5817751A (en) * | 1994-06-23 | 1998-10-06 | Affymax Technologies N.V. | Method for synthesis of diketopiperazine and diketomorpholine derivatives |
| GB2326639A (en) | 1997-06-18 | 1998-12-30 | Merck & Co Inc | Piperazine Oxytocin Receptor Antagonists |
| US5968938A (en) * | 1997-06-18 | 1999-10-19 | Merck & Co., Inc. | Piperazine oxytocin receptor antagonists |
| CN1291892A (zh) | 1998-01-27 | 2001-04-18 | 阿温蒂斯药物制品公司 | 取代的氧代氮杂杂环基因子Xa抑制剂 |
| WO1999038844A1 (en) | 1998-01-29 | 1999-08-05 | Aventis Pharmaceuticals Products Inc. | Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound |
| AU3087099A (en) * | 1998-03-16 | 1999-10-11 | Ontogen Corporation | Piperazines as inhibitors of fructose-1,6-bisphosphatase (FBPase) |
| GB2372740A (en) | 2001-01-17 | 2002-09-04 | Xenova Ltd | Diketopiperazines |
| GB0130677D0 (en) * | 2001-12-21 | 2002-02-06 | Glaxo Group Ltd | Medicaments and novel compounds |
| US20030229001A1 (en) | 2002-01-31 | 2003-12-11 | Pfizer Inc. | Treatment of male sexual dysfunction |
| GB0314738D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Novel compounds |
| GB0314733D0 (en) | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| GB0414093D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414100D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0414092D0 (en) * | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| GB0428235D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Novel compounds |
| EP2760473A1 (en) | 2011-09-27 | 2014-08-06 | Biomed Valley Discoveries, Inc. | Compositions and methods of treating gliomas |
-
2003
- 2003-06-24 GB GB0314738A patent/GB0314738D0/en not_active Ceased
-
2004
- 2004-06-22 MY MYPI20042430 patent/MY140653A/en unknown
- 2004-06-22 PL PL04740230T patent/PL1641787T3/pl unknown
- 2004-06-22 AU AU2004251868A patent/AU2004251868B2/en not_active Ceased
- 2004-06-22 DE DE200460006268 patent/DE602004006268T2/de active Active
- 2004-06-22 EP EP04740230A patent/EP1641787B1/en active Active
- 2004-06-22 US US10/561,498 patent/US8071594B2/en not_active Expired - Fee Related
- 2004-06-22 KR KR1020057024715A patent/KR101131378B1/ko active IP Right Grant
- 2004-06-22 DK DK04740230T patent/DK1641787T3/da active
- 2004-06-22 ES ES04740230T patent/ES2285474T3/es active Active
- 2004-06-22 WO PCT/EP2004/006814 patent/WO2005000840A1/en active IP Right Grant
- 2004-06-22 AT AT04740230T patent/ATE361295T1/de active
- 2004-06-22 RU RU2006101859A patent/RU2343152C2/ru not_active IP Right Cessation
- 2004-06-22 CA CA 2530310 patent/CA2530310C/en not_active Expired - Fee Related
- 2004-06-22 MX MXPA05014068A patent/MXPA05014068A/es active IP Right Grant
- 2004-06-22 BR BRPI0411729 patent/BRPI0411729A/pt not_active Application Discontinuation
- 2004-06-22 AR ARP040102182 patent/AR044869A1/es not_active Application Discontinuation
- 2004-06-22 CN CNB2004800178348A patent/CN100404532C/zh not_active Expired - Fee Related
- 2004-06-22 JP JP2006516041A patent/JP5128126B2/ja not_active Expired - Fee Related
- 2004-06-22 NZ NZ544006A patent/NZ544006A/en unknown
- 2004-06-22 PT PT04740230T patent/PT1641787E/pt unknown
- 2004-06-22 CN CNA2008101088194A patent/CN101597282A/zh active Pending
- 2004-06-23 TW TW093118010A patent/TWI340745B/zh not_active IP Right Cessation
-
2005
- 2005-12-06 ZA ZA200509890A patent/ZA200509890B/en unknown
- 2005-12-12 IL IL172529A patent/IL172529A/en active IP Right Grant
- 2005-12-21 EG EGNA2005000854 patent/EG24929A/xx active
- 2005-12-21 MA MA28677A patent/MA27887A1/fr unknown
-
2006
- 2006-01-20 IS IS8248A patent/IS2463B/is unknown
- 2006-01-24 NO NO20060383A patent/NO332677B1/no not_active IP Right Cessation
- 2006-08-22 HK HK06109351A patent/HK1088910A1/xx not_active IP Right Cessation
-
2007
- 2007-06-29 HR HR20070286T patent/HRP20070286T3/hr unknown
- 2007-07-24 CY CY071100990T patent/CY1107703T1/el unknown
-
2011
- 2011-09-13 US US13/231,211 patent/US8357685B2/en not_active Expired - Fee Related
-
2012
- 2012-12-14 US US13/715,433 patent/US20130102783A1/en not_active Abandoned
-
2013
- 2013-11-05 US US14/072,376 patent/US8937179B2/en not_active Expired - Fee Related
-
2014
- 2014-12-15 US US14/570,812 patent/US20150105387A1/en not_active Abandoned
-
2015
- 2015-11-20 US US14/946,920 patent/US9452169B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053569D0 (no) | Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som nevrokininantagonister | |
| DK1480955T3 (da) | O-cyclopropyl-carboxanilider og deres anvendelse som fungicider | |
| IS8320A (is) | N-staðgengnir pýrasólýl-amidýl-bensimidasólýl | |
| ATE418924T1 (de) | Marknagel | |
| DK1472255T3 (da) | Aza-arylpiperaziner | |
| DK1472256T3 (da) | Piperidinderivater | |
| IS2463B (is) | Útskipt díketópíperasín og notkun þeirra sem oxytósínmótlyfja | |
| DE602004019555D1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und -naphthyridone | |
| ATE462365T1 (de) | Marknagel | |
| NO20054225D0 (no) | Benzamid-derivater som oksytocin-agonister og vasopressin-antagonister | |
| NO20053598D0 (no) | Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister. | |
| NO20054172D0 (no) | Nye blandinger | |
| ATE514681T1 (de) | N-substituierte pyrazolylcarboxanilide | |
| ATE444953T1 (de) | Substituierte spirobenzazepine | |
| DE50311770D1 (de) | Oberfräse | |
| FR2852619B1 (fr) | Echafaudage volant | |
| DE60315718D1 (de) | Ventrikuläre pulsraten-stabilisation | |
| SE0301314L (sv) | Klammer | |
| ES1066792Y (es) | Grapa | |
| SE0302332D0 (sv) | New use I | |
| NO20031983D0 (no) | Brannslukning | |
| DOS2003000768S (es) | Dispersador | |
| FI20031730A0 (fi) | Halkaisukirves | |
| SE0301797D0 (sv) | New use V | |
| SE0300106D0 (sv) | New use |